Want to see RARE full AI Analyst Report?

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

1,307 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RARE Analyst Ratings

Moderate Buy

10 Buy

10 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Ultragenyx

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$28.47

▲(7.61% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $28.47 with a high forecast of $68.00 and a low forecast of $16.00. The average price target represents a 7.61% change from the last price of $26.46.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","42":"$42","69":"$69","28.5":"$28.5","55.5":"$55.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.473684210526315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,28.5,42,55.5,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.81,29.055384615384614,32.30076923076923,35.54615384615384,38.79153846153846,42.036923076923074,45.28230769230769,48.527692307692305,51.77307692307692,55.01846153846154,58.263846153846146,61.50923076923077,64.75461538461538,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.81,26.0148987854251,26.2197975708502,26.4246963562753,26.629595141700403,26.834493927125504,27.039392712550608,27.24429149797571,27.44919028340081,27.65408906882591,27.858987854251012,28.063886639676113,28.268785425101214,{"y":28.473684210526315,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.81,25.055384615384614,24.30076923076923,23.546153846153846,22.79153846153846,22.036923076923078,21.28230769230769,20.527692307692305,19.77307692307692,19.018461538461537,18.263846153846153,17.50923076923077,16.754615384615384,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.91,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.81,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$68.00

Average Price Target$28.47

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-Gartner

Evercore ISI

$16→$18

Hold

-31.97%

Downside

Reiterated

09/21/26

Ultragenyx price target raised to $18 from $16 at Evercore ISIUltragenyx price target raised to $18 from $16 at Evercore ISI

Maxwell Skor

Morgan Stanley

$18→$20

Hold

-24.41%

Downside

Assigned

09/21/26

Morgan Stanley Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

Joseph Schwartz

Leerink Partners

$33

Buy

24.72%

Upside

Reiterated

09/18/26

Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Laura Chico

Wedbush

$23

Hold

-13.08%

Downside

Reiterated

09/18/26

Analysts Offer Insights on Healthcare Companies: Heart Test Laboratories, Inc. (NASDAQ: HSCS), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Abeona Therapeutics (NASDAQ: ABEO)

Whitney Ijem

Canaccord Genuity

$37→$39

Buy

47.39%

Upside

Reiterated

09/18/26

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity

Sami Corwin

William Blair

―

Hold

―

Reiterated

09/18/26

Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts

Yigal Nochomovitz

Citi

$31→$32

Buy

20.94%

Upside

Reiterated

09/18/26

Ultragenyx price target raised to $32 from $31 at CitiUltragenyx price target raised to $32 from $31 at Citi

Tazeen Ahmad

Bank of America Securities

$20

Hold

-24.41%

Downside

Reiterated

09/18/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Envista Holdings (NYSE: NVST) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Eliana Merle

Barclays

$32→$35

Buy

32.28%

Upside

Reiterated

09/18/26

Analysts Offer Insights on Healthcare Companies: Helus Pharma (NASDAQ: HELP), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Novavax (NASDAQ: NVAX)

Benjamin Burnett

Wells Fargo

$18

Hold

-31.97%

Downside

Assigned

09/18/26

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Globus Medical (NYSE: GMED)

Kristen Kluska

Cantor Fitzgerald

$33→$39

Buy

47.39%

Upside

Reiterated

09/17/26

Ultragenyx price target raised to $39 from $33 at Cantor FitzgeraldUltragenyx price target raised to $39 from $33 at Cantor Fitzgerald

Salveen Richter

Goldman Sachs

$28→$19

Hold

-28.19%

Downside

Reiterated

09/04/26

Goldman Sachs Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Yaron Werber

TD Cowen

$49→$18

Buy

-31.97%

Downside

Assigned

09/03/26

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Edwards Lifesciences (NYSE: EW)

Anupam Rama

J.P. Morgan

$80→$36

Hold

36.05%

Upside

Downgraded

09/03/26

Ultragenyx downgraded to Neutral from Overweight at JPMorganUltragenyx downgraded to Neutral from Overweight at JPMorgan

Ram Selvaraju

H.C. Wainwright

$50→$25

Buy

-5.52%

Downside

Reiterated

09/03/26

Ultragenyx: GTX-102 Setback Triggers Price-Target Cut to $25, but Buy Rating Maintained on Pipeline Upside

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-Gartner

Evercore ISI

$16→$18

Hold

-31.97%

Downside

Reiterated

09/21/26

Ultragenyx price target raised to $18 from $16 at Evercore ISIUltragenyx price target raised to $18 from $16 at Evercore ISI

Maxwell Skor

Morgan Stanley

$18→$20

Hold

-24.41%

Downside

Assigned

09/21/26

Morgan Stanley Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

Joseph Schwartz

Leerink Partners

$33

Buy

24.72%

Upside

Reiterated

09/18/26

Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Laura Chico

Wedbush

$23

Hold

-13.08%

Downside

Reiterated

09/18/26

Analysts Offer Insights on Healthcare Companies: Heart Test Laboratories, Inc. (NASDAQ: HSCS), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Abeona Therapeutics (NASDAQ: ABEO)

Whitney Ijem

Canaccord Genuity

$37→$39

Buy

47.39%

Upside

Reiterated

09/18/26

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity

Sami Corwin

William Blair

―

Hold

―

Reiterated

09/18/26

Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts

Yigal Nochomovitz

Citi

$31→$32

Buy

20.94%

Upside

Reiterated

09/18/26

Ultragenyx price target raised to $32 from $31 at CitiUltragenyx price target raised to $32 from $31 at Citi

Tazeen Ahmad

Bank of America Securities

$20

Hold

-24.41%

Downside

Reiterated

09/18/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Envista Holdings (NYSE: NVST) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Eliana Merle

Barclays

$32→$35

Buy

32.28%

Upside

Reiterated

09/18/26

Analysts Offer Insights on Healthcare Companies: Helus Pharma (NASDAQ: HELP), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Novavax (NASDAQ: NVAX)

Benjamin Burnett

Wells Fargo

$18

Hold

-31.97%

Downside

Assigned

09/18/26

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Globus Medical (NYSE: GMED)

Kristen Kluska

Cantor Fitzgerald

$33→$39

Buy

47.39%

Upside

Reiterated

09/17/26

Ultragenyx price target raised to $39 from $33 at Cantor FitzgeraldUltragenyx price target raised to $39 from $33 at Cantor Fitzgerald

Salveen Richter

Goldman Sachs

$28→$19

Hold

-28.19%

Downside

Reiterated

09/04/26

Goldman Sachs Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Yaron Werber

TD Cowen

$49→$18

Buy

-31.97%

Downside

Assigned

09/03/26

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Edwards Lifesciences (NYSE: EW)

Anupam Rama

J.P. Morgan

$80→$36

Hold

36.05%

Upside

Downgraded

09/03/26

Ultragenyx downgraded to Neutral from Overweight at JPMorganUltragenyx downgraded to Neutral from Overweight at JPMorgan

Ram Selvaraju

H.C. Wainwright

$50→$25

Buy

-5.52%

Downside

Reiterated

09/03/26

Ultragenyx: GTX-102 Setback Triggers Price-Target Cut to $25, but Buy Rating Maintained on Pipeline Upside

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

LGNDLigand Pharma

DNLIDenali Therapeutics

ACHVAchieve Life Sciences

PMNProMIS Neurosciences

CELCCelcuity

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months

Joon LeeTruist Financial

Success Rate

13/23 ratings generated profit

Average Return

+1.75%

Copying Joon Lee's trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +1.75% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

8/23 ratings generated profit

Average Return

-4.63%

Copying Joon Lee's trades and holding each position for 1 Year would result in 34.78% of your transactions generating a profit, with an average return of -4.63% per trade.

2 Years

Yaron WerberTD Cowen

Success Rate

5/31 ratings generated profit

Average Return

-28.76%

Copying Yaron Werber's trades and holding each position for 2 Years would result in 16.13% of your transactions generating a profit, with an average return of -28.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RARE has received 43 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the past 3 months is 28.47.

Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$0.93 with a range of -$1.29 to $0.75. The previous quarter’s EPS was -$0.90. RARE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $183.19M with a range of $161.00M to $198.20M. The previous quarter’s sales results were $214.00M. RARE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?

Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 28.47.

What is RARE’s upside potential, based on the analysts’ average price target?

Ultragenyx Pharmaceutical has 7.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RARE a Buy, Sell or Hold?

Ultragenyx Pharmaceutical has a consensus rating of Moderate Buy which is based on 10 buy ratings, 10 hold ratings and 0 sell ratings.

What is Ultragenyx Pharmaceutical’s price target?

The average price target for Ultragenyx Pharmaceutical is 28.47. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $16.00. The average price target represents 7.61% Increase from the current price of $26.46.

What do analysts say about Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of RARE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

RARE Analyst Ratings

RARE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ultragenyx Pharmaceutical

RARE Analyst Recommendation Trends

RARE Financial Forecast

RARE Earnings Forecast

RARE Sales Forecast

RARE Stock Forecast FAQ

Detailed List of Analyst Forecasts